The Truth About GLP-1s and Thyroid Cancer: Black Box Warning Explained

If you have read the Wegovy or Ozempic prescribing information — or if you have heard anything about GLP-1 medications and thyroid cancer — you have almost certainly encountered the black box warning. It sits at the very top of the label, in a bordered box, and it mentions thyroid C-cell tumors and medullary thyroid carcinoma (MTC). For many patients and their families, that warning is deeply alarming. The purpose of this article is to explain exactly where that warning comes from, what it actually means, what human data show, and why the FDA still approves these medications for use in the overwhelming majority of patients.

At Scale Solutions in Savannah, Pooler, and Hinesville GA, Dr. Donald L. Gates MD evaluates every patient’s personal and family medical history before prescribing any GLP-1 medication, ensuring that those with relevant contraindications are identified upfront. Understanding the evidence is the foundation of that conversation.

What the Black Box Warning Actually Says

The FDA black box warning on semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) states that in rodent studies, these medications caused dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma. It warns that the drugs are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It also notes that the relevance of these rodent findings to humans is unknown.

That last sentence is crucial: the relevance to humans is unknown. This is not a confirmed human risk. It is a precautionary warning based on animal data — data derived from rodent models that express GLP-1 receptors on thyroid C-cells in a pattern that differs from human thyroid physiology.

Why Rodents and Humans Respond Differently

Rodents — particularly rats and mice used in carcinogenicity studies — have a much higher density of GLP-1 receptors on their thyroid C-cells than humans do. In rodent models, sustained pharmacological stimulation of these receptors over the animal’s lifetime produces C-cell hyperplasia and, at high doses, carcinoid tumors. Human thyroid C-cells express GLP-1 receptors at much lower levels and appear to respond differently to GLP-1 receptor agonism.

This biological difference is why the FDA classifies this as a class-wide precautionary warning rather than a confirmed human carcinogen risk. Drug labels are required to report all findings from animal studies, even when translatability to humans is uncertain or unlikely. The warning does not mean that GLP-1 medications cause thyroid cancer in humans — it means that this possibility cannot be excluded based on current evidence and that patients with pre-existing risk factors for MTC should not use these medications.

What Human Clinical Trial Data Show

The most important question is: what have long-term human trials actually found? The large cardiovascular outcomes trials — including LEADER (liraglutide, 9,340 patients, 3.8-year median follow-up), SUSTAIN-6 (semaglutide, 3,297 patients, 2-year follow-up), and SELECT (semaglutide, 17,604 patients, nearly 40-month mean follow-up) — all monitored calcitonin levels (a biomarker for C-cell activity) and tracked thyroid cancer diagnoses.

Across these trials, the SELECT trial found that malignant neoplasms occurred in 4.8% of semaglutide participants versus 4.7% of placebo participants — a negligible and statistically non-significant difference. Calcitonin levels did not increase meaningfully with treatment. In the SURMOUNT tirzepatide trials, no cases of medullary thyroid cancer were reported in any treatment arm.

Data from cardiovascular outcome trials suggest that three-year exposure to GLP-1 receptor agonists did not meaningfully affect calcitonin levels or increase rates of new MTC diagnoses, as reviewed in Endocrine Connections (2023). These are the most robust prospective human datasets available.

The Bezin et al. 2023 Study: What It Found and What It Didn’t

In 2023, a retrospective pharmacoepidemiological study by Bezin and colleagues (discussed in Diabetes Care, 2023) attracted significant attention. Using a large French national health insurance database, the researchers reported that GLP-1 receptor agonist use for one to three years was associated with an increased hazard ratio of 1.58 for all thyroid cancers and 1.78 for medullary thyroid cancer compared with insulin users.

This study generated headlines — but it has important limitations that must be understood. First, it was a retrospective observational study, not a randomized controlled trial; unmeasured confounding is a significant concern. Second, the absolute number of MTC cases was very small, limiting statistical power. Third, the comparison group (insulin users) may not represent an ideal control population. Fourth, the study design cannot distinguish between GLP-1 medications causing thyroid cancer and GLP-1 medications leading to increased medical surveillance that detects pre-existing thyroid abnormalities. The same authors and commentators have noted that the cardiovascular and renal benefits of GLP-1 receptor agonists — well established across large RCTs — are expected to substantially outweigh the potential thyroid cancer signal even if it proves real.

Who Should Not Take GLP-1 Medications

The FDA contraindications for semaglutide and tirzepatide are clear and clinically appropriate:

• Personal history of medullary thyroid carcinoma (MTC): Do not use GLP-1 receptor agonists.
• Family history of MTC: Do not use GLP-1 receptor agonists.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Do not use GLP-1 receptor agonists.

These are firm contraindications, not soft precautions. They are based on the precautionary principle applied appropriately to a population with pre-existing risk for the tumor type identified in animal studies. For the vast majority of patients — those without these specific personal or family histories — the contraindication does not apply.

Calcitonin Monitoring: What Dr. Gates Does

At Scale Solutions, Dr. Gates takes the thyroid cancer precaution seriously without being paralyzed by it. Before initiating GLP-1 therapy, he obtains a detailed personal and family history covering thyroid conditions, MTC, and MEN 2. For patients with any family history of thyroid tumors, he may obtain a baseline serum calcitonin level, which is a sensitive marker for C-cell activity. Patients are instructed to report any neck mass, difficulty swallowing, persistent hoarseness, or shortness of breath at any point during treatment.

This approach — thorough screening and appropriate vigilance without abandoning a highly effective therapy for the many — reflects current clinical best practices and the recommendations of the Endocrine Society and the American Thyroid Association, which have not called for routine calcitonin screening in all patients starting GLP-1 therapy but do endorse personalized risk assessment.

Putting the Risk in Perspective

Medullary thyroid carcinoma is a rare cancer. It accounts for approximately 1–2% of all thyroid cancers in the United States, with an incidence of roughly 1–2 cases per 100,000 people per year. Most MTC cases (approximately 75%) are sporadic rather than hereditary. The background rate of MTC is extremely low in the general population, and even if the Bezin et al. signal were confirmed as causal — which remains uncertain — the absolute number of additional cases attributable to GLP-1 therapy would be very small.

Compare this to the well-documented harms of untreated obesity: cardiovascular disease, type 2 diabetes, sleep apnea, non-alcoholic fatty liver disease, osteoarthritis, and cancers including endometrial, breast, and colorectal. The risk-benefit calculation for eligible patients who are properly screened is firmly favorable toward treatment. For more on the broader safety profile of these medications and GLP-1 news in coastal Georgia, explore our full resource series.

The Bottom Line

The GLP-1 black box warning for thyroid C-cell tumors is based on rodent data in animals with thyroid physiology that differs from humans. Long-term human clinical trials including SELECT, LEADER, and SUSTAIN-6 — covering tens of thousands of patients over multiple years — have not shown a significant increase in thyroid cancer diagnoses. The Bezin et al. observational study raised a signal worth monitoring but has important methodological limitations and cannot establish causation. For patients without a personal or family history of MTC or MEN 2, GLP-1 medications remain a medically appropriate treatment option when prescribed and monitored by an experienced physician.

Schedule Your Evaluation with Dr. Gates

Dr. Donald L. Gates MD at Scale Solutions takes a thorough, personalized approach to every GLP-1 evaluation — reviewing your personal and family medical history, discussing contraindications openly, and ensuring that the choice to initiate treatment is made with full information. We serve patients throughout Savannah, Pooler, and Hinesville, GA. Call (912) 352-7546 or email info@scale-solutions.com to schedule your consultation.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-1 medications have FDA-approved contraindications that must be evaluated by a licensed physician on an individual basis. The information presented reflects published scientific literature and FDA labeling as of the date of publication. Always consult a qualified healthcare provider before starting any prescription medication.

Frequently Asked Questions

Does the thyroid warning mean I should not take semaglutide?

The warning is a contraindication only for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). For patients without these specific risk factors, the warning does not prohibit use. Your physician will review your medical and family history to determine whether any contraindication applies to you specifically before prescribing.

Should I have my calcitonin levels checked before starting a GLP-1?

Routine calcitonin screening is not currently required by the FDA or mandated by major endocrinology guidelines for all patients starting GLP-1 therapy. However, for patients with a personal or family history of thyroid cancer or thyroid nodules, baseline calcitonin measurement and thyroid evaluation may be clinically appropriate. Dr. Gates makes this determination individually based on each patient’s history.

What symptoms would suggest a thyroid problem while on a GLP-1?

Symptoms that warrant prompt medical evaluation include a palpable lump or mass in the neck, unexplained hoarseness or changes in voice, difficulty swallowing, shortness of breath, or persistent neck pain. These symptoms can have many causes but should always be reported to your physician, particularly while on any long-term medication. At Scale Solutions, we instruct all patients to contact us if they develop any of these symptoms.

Did the large clinical trials find any thyroid cancers in GLP-1 patients?

The SELECT trial, which followed 17,604 patients for nearly 40 months, found that malignant neoplasms occurred in 4.8% of semaglutide participants and 4.7% of placebo participants — a non-significant difference. No cases of medullary thyroid cancer were reported in the SURMOUNT tirzepatide trials. The cardiovascular outcomes trials for liraglutide (LEADER) similarly showed no significant thyroid cancer signal after years of follow-up.

What is medullary thyroid carcinoma and how common is it?

Medullary thyroid carcinoma (MTC) is a cancer of the thyroid C-cells, which produce calcitonin. It is rare, accounting for roughly 1 to 2 percent of all thyroid cancers in the United States, with an incidence of approximately 1 to 2 cases per 100,000 people per year. About 75 percent of MTC cases are sporadic (not hereditary). The inherited form is associated with mutations in the RET proto-oncogene and occurs in the context of MEN 2 syndrome, for which GLP-1 use is specifically contraindicated.